Navigation Links
Phase 2 Data for Ultra-Long-Acting Insulin Degludec Shows the Potential to Effectively Lower Blood Sugar, Including When Used Three Times a Week
Date:6/25/2010

ORLANDO, Fla., June 25 /PRNewswire-FirstCall/ -- Novo Nordisk today presented phase 2 proof-of-concept data for its investigational insulin degludec, an ultra-long-acting basal insulin, which demonstrated the potential to help achieve target glycemic control when used once daily or three times weekly. These data were presented at the 70th Scientific Sessions of the American Diabetes Association (ADA).(1)

These phase 2 studies showed that insulin degludec helped improve glucose control. In one study, after 16 weeks of treatment with insulin degludec, mean HbA1c reductions were similar across the once-daily and three-times-weekly insulin degludec groups (-1.3% and -1.5% respectively) and comparable to insulin glargine (-1.5%).(2)

In this study, 77% of patients treated with insulin degludec three times weekly did not experience any confirmed hypoglycemia (defined as low blood glucose levels or episodes that required assistance). This result was similar in the study arm using insulin glargine once daily. Of those patients using insulin degludec once daily, 92% did not experience any confirmed hypoglycemia. A formal statistical test was not possible due to low number of patients in this study (60-62 in each arm).

"Insulin degludec has shown the potential to help deliver improvements in glycemic control with less than one daily injection," said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk. "The low rate of hypoglycemia after once-daily insulin degludec administration, as well as the potential to be used three times weekly in people with type 2 diabetes will be further evaluated in our pivotal phase 3 trials in the BEGIN™ and BOOST™ programs."

Insulin degludec/insulin aspart (I
'/>"/>

SOURCE Novo Nordisk
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
2. Sinapis Pharma Commences Phase I Trial
3. Zydus Novel Orally Administered GLP-1 Agonist - ZYOG1 to treat Diabetes and Obesity Enters Phase I Clinical Trial
4. InteKrin Therapeutics to Present Phase 2b Clinical Data for Edema at the 2010 American Diabetes Association Annual Meeting
5. DURECT Reports Data From European Phase IIb Hysterectomy Study of POSIDUR(TM) (SABER(TM)-Bupivacaine)
6. Trius Therapeutics Obtains Special Protocol Assessment With FDA for Phase 3 Study of Torezolid Phosphate
7. Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
8. MultiCell Hires Clinical Research Organization to Manage MCT-125 Phase IIb Clinical Trial
9. Updated Results from Phase 2 Trial Demonstrate Prolonged Hematologic Relapse-Free Survival of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
10. Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
11. Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... a privately-held medical products and technologies company, today announced ... Officer of the company, effective December 22, 2014. ... Board of Directors of ConvaTec thanks Mr. Berger for ... years," said Magnus Lundberg , the Chairman of ... company is well positioned for the future."  The company ...
(Date:12/22/2014)... Dec. 22, 2014  Mark Farrah Associates (MFA), ... a summary of the 2015 marketplace exchange projections ... According to a recent ASPE ... Evaluation, Department of Health and Human Services) report, ... individual medical plans through the Marketplace as of ...
(Date:12/22/2014)... , Dec. 22, 2014 TWi Biotechnology, ... of Allowance for AC-201, TWi Biotechnology,s lead drug ... China for patent application ... pharmaceutically acceptable salts, active metabolite for treatment of ... methods of treatment using AC-201 for type II ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Insights into the Marketplace and Individual Market Growth 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3
... Oct. 3, 2011 To help frustrated nighttime nasal ... chronic nasal congestion and trouble with sleep, the makers ... to identify the 20 Most Congested Cities in the ... metropolitan areas where residents are most challenged by congestion ...
... MURRIETA, Calif., Oct. 3, 2011 ... recently took delivery of their long-awaited WASP® (Walk ... Module.  The acquisition was concomitant with the inauguration ... ongoing efforts to optimize patient care by consolidating ...
Cached Medicine Technology:20 Most Congested Cities in U.S. Unveiled 220 Most Congested Cities in U.S. Unveiled 320 Most Congested Cities in U.S. Unveiled 4COPAN WASP® Lands at Prestigious Boston Medical Center 2COPAN WASP® Lands at Prestigious Boston Medical Center 3
(Date:12/22/2014)... NC (PRWEB) December 22, 2014 ... the current Ebola virus epidemic are receiving ... U.S. government agencies, nongovernmental organizations (NGOs) and ... remains ongoing, healthcare workers, emergency responders, patients ... technologies such as the CmTP MediDefense ...
(Date:12/22/2014)... The Bob Woodruff Foundation will ... more than $5 million in programs and organizations ... families. , This includes $1.3 million in grants ... with: veteran entrepreneurship; community impact; vocational training; transportation; ... injured veterans. , “The needs of those injured ...
(Date:12/22/2014)... December 22, 2014 Give a loved ... the gift of health and vitality. , For a ... three top-selling anti-aging formulas in special Holiday Wellness gift ... delivery. , Each bottle contains cutting-edge, proven nutritional ... don't work as well as we age. ...
(Date:12/22/2014)... Xarelto Lawsuit News : Alonso Krangle ... granted a request to centralize pending and subsequent ... District of Louisiana. The U.S. Judicial Panel On Multidistrict ... transfer over 50 Xarelto cases–21 lawsuits and 30 potential ... for consolidation under U.S. District Judge Eldon E. Fallon. ...
(Date:12/22/2014)... 2014 Christmas is days away, and last ... and easy solution that will please: the Sublime Gift ... from from $25 up to $350," says Kathy Heshelow, founder ... and a wide array of skin care products and Skin ... expiration dates. , Gift delivery past shipping deadlines, or ...
Breaking Medicine News(10 mins):Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 3Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 4Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 6Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 7Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4
... ... in the parts washing industry. Midbrook has extensive experience washing parts and equipment in a ... Washing facility to help a North American automotive parts supplier solve a de-rusting issue. ... (Vocus) October 6, 2009 -- ...
... ... important factors when selecting a Medicare plan , ... Belleville, Ill. (Vocus) – People with disabilities have crucial ... , a nationwide provider of Social Security disability representation and Medicare services. , ...
... ... Faculty Investigator, made major discoveries in telomere biochemistry and regulation , ... Cold Spring Harbor, NY (Vocus) October ... has been named a Nobel Laureate, Cold Spring Harbor Laboratory President Bruce Stillman said, ...
... ... Securities Exchange-listed oncology biotechnology company, announced today an AU$7,230,000 investment by SpringTree Special ... financial advisor to SpringTree,s general partner SpringTree Global Investors, LLC on the transaction. ... ...
... , YORKTOWN HEIGHTS, N.Y., Oct. 6 In an effort to ... ) scientists are drilling nano-sized holes in computer-like chips and passing ... within their genetic code. , View video: ... , For an ongoing conversation on ...
... NEWNAN, Ga., Oct. 6 The authors of ... Vascular Disease Management conclude that the micro-bland embolization ... better clinical outcomes. Franco Orsi, MD, PhD, and ... in Rome conclude that small, tightly calibrated Embozene(TM) ...
Cached Medicine News:Health News:Midbrook Production Washing A Valuable Partner 2Health News:Midbrook Production Washing A Valuable Partner 3Health News:People with Disabilities Face Unique Healthcare Coverage Challenges, Allsup Says 2Health News:People with Disabilities Face Unique Healthcare Coverage Challenges, Allsup Says 3Health News:People with Disabilities Face Unique Healthcare Coverage Challenges, Allsup Says 4Health News:People with Disabilities Face Unique Healthcare Coverage Challenges, Allsup Says 5Health News:People with Disabilities Face Unique Healthcare Coverage Challenges, Allsup Says 6Health News:Cold Spring Harbor Laboratory's President Congratulates Alumna on Winning Nobel Prize 2Health News:KTA Capital Advises SpringTree Global Investors on an AU$7.2 Million Investment in HealthLinx Ltd 2Health News:IBM Research Aims to Build Nanoscale DNA Sequencer to Help Drive Down Cost of Personalized Genetic Analysis 2Health News:IBM Research Aims to Build Nanoscale DNA Sequencer to Help Drive Down Cost of Personalized Genetic Analysis 3Health News:IBM Research Aims to Build Nanoscale DNA Sequencer to Help Drive Down Cost of Personalized Genetic Analysis 4Health News:Scientific Paper Supports Micro-Bland Embolization Technique for Liver Cancer With Embozene(TM) Microspheres 2
... Self-contained kits provide convenience and cost control. ... care trays offer a variety of wound ... management of the tracheostomized patient. , ... and trays with disposable inner cannula for ...
Disposable tracheostomy care tray....
Disposable tracheostomy care tray....
Disposable tracheostomy care tray....
Medicine Products: